Atlas Trials

GBG Forschungs GmbH

42 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch GBG Forschungs GmbH

RecordFirmDate
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (NCT06201234)GBG Forschungs GmbH2024-12-13
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer (NCT06607757)GBG Forschungs GmbH2024-12-04
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (NCT05306041)GBG Forschungs GmbH2023-01-02
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (NCT04595565)GBG Forschungs GmbH2020-10-28
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (NCT03555877)GBG Forschungs GmbH2018-03-15
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (NCT03355157)GBG Forschungs GmbH2018-03-01

Track GBG Forschungs GmbH automatically

Every clearance here is in the API, with alerts when new ones post.